"The immunotherapy response assessment for neuro-oncology (iRANO) criteria have been developed as a modification of RANO criteria to address the challenges of emerging novel immunotherapy for high-grade gliomas 1. Although these criteria have been primarily for the purposes of standardising assessment of treatment response in the setting of clinical trials, they offer important guiding principles for everyday reporting."
"Key differences between iRANO and RANO criteria"
"same as RANO progressive disease criteria"
Expected headings
"Key differences between iRANO and RANO criteria"
"Progressive disease"
"Role of histopathology"